Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Simulations Plus (SLP) Readies Fiscal Q4 2026 Earnings Report

Simulations Plus (SLP) Readies Fiscal Q4 2026 Earnings Report

Key Takeaways

  • Simulations Plus, Inc. (SLP), a provider of modeling and simulation software for drug development, is expected to report fiscal fourth quarter 2026 results (for the quarter ended August 31, 2026) after the market closes on Thursday, October 29, 2026.
  • Wall Street consensus calls for earnings per share (EPS) of $0.09 on revenue of approximately $17.44 million, according to market estimates.
  • The comparison is challenging: in the same quarter a year earlier, the company posted EPS of $0.10 on revenue of $17.46 million.
  • Simulations Plus has beaten consensus EPS estimates in six of its last eight quarters, most recently reporting $0.30 per share in fiscal Q3 2026 against a $0.23 estimate.
  • Management's fiscal 2026 guidance calls for EPS of $0.75 to $0.85 and revenue of $79 million to $82 million.

Earnings Context and Why It Matters

Simulations Plus closes out a fiscal year that has featured strong mid-year momentum and a mixed start. The company develops software used by pharmaceutical and biotechnology companies to model and simulate drug behavior, helping clients streamline research and development and regulatory submissions. Its fiscal fourth quarter often carries seasonal weight as contracts and renewals land before the August 31 year-end. Investors will be watching whether the company can sustain the revenue strength seen in recent quarters while managing the softer growth implied by consensus estimates for the period. The results will also frame how management enters fiscal 2027, making this report a meaningful barometer for both near-term execution and longer-term demand across the life sciences software market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Earnings Expectations

Analysts expect Simulations Plus to report EPS of $0.09 on revenue of roughly $17.44 million for the fiscal fourth quarter of 2026. That would represent a modest year-over-year decline from the prior-year quarter, when the company delivered EPS of $0.10 on revenue of $17.46 million. For context, the company reported fiscal Q3 2026 EPS of $0.30 on revenue of approximately $21.89 million, comfortably ahead of the $0.23 consensus EPS estimate. Management's full-year fiscal 2026 outlook projects EPS of $0.75 to $0.85 and revenue of $79 million to $82 million, so the fourth-quarter result will help determine whether the company lands within that guided range. Investors are likely to focus on software revenue growth, services mix, and any update to the company's forward outlook. From what I see, the year-over-year comparison here is worth monitoring closely.

Market Reaction and Investor Sentiment

Sentiment heading into the report is measured, reflecting the soft year-over-year comparison embedded in consensus estimates. Simulations Plus has a track record of delivering earnings surprises, exceeding EPS expectations in six of its last eight quarters, which may temper bearish positioning. However, the fiscal fourth quarter has occasionally produced in-line or modest results given the seasonality of the business. Key risk factors include the timing of large software contracts, potential shifts in customer research and development budgets, and any foreign-exchange or acquisition-related effects. Investors will also parse management's commentary on the demand environment for biosimulation and cheminformatics software as a signal for the coming fiscal year. One thing that stands out is the company's history of beats, which could influence how the market digests any shortfall.

Forward Outlook and Key Factors to Monitor

Following the earnings report, investors will want to watch several forward-looking signals. First, any update to guidance for fiscal 2027 will be closely read, as it sets the baseline for growth expectations over the next twelve months.

Second, the trajectory of software revenue versus services revenue matters. Software, particularly subscription-based offerings, is generally viewed as higher quality and more recurring, so the mix between these segments can influence how the market values the results.

Third, keep an eye on operating margins and expense trends. Continued investment in research and development and in the company's expanding product portfolio could pressure near-term profitability even as it supports longer-term growth.

Finally, broader industry dynamics in pharmaceutical research and development spending, as well as any commentary on client renewal activity, will help investors assess whether demand remains resilient. While these factors will not resolve in a single quarter, they collectively shape the outlook for Simulations Plus heading into fiscal 2027.

Using Tickeron’s AI Tools in My Research

I often turn to Tickeron’s AI Screener when preparing for earnings like this one. The tool lets me quickly filter stocks by fundamentals, technical patterns, and AI signals, helping me compare SLP against peers in the life sciences software space. It has become a regular part of how I narrow down ideas and check context before reports like this hit the wire. In my view, it adds a structured layer to the analysis without replacing the need to review the actual numbers and guidance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SLP

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Aroon Indicator for SLP shows an upward move is likely

SLP's Aroon Indicator triggered a bullish signal on November 05, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 196 similar instances where the Aroon Indicator showed a similar pattern. In 95 of the 196 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 48%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis
Bearish Trend Analysis
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of software for use in pharmaceutical research

Industry ServicestotheHealthIndustry

Industry
Packaged Software
Address
800 Park Offices Drive
Phone
+1 661 723-7723
Employees
213
Web
https://www.simulations-plus.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.